CRIS Current Research Information System

FOLLO, MATILDE YUNG
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.355
EU - Europa 4.910
AS - Asia 2.350
AF - Africa 413
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 12
SA - Sud America 8
Totale 14.064
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.331
IT - Italia 1.213
GB - Regno Unito 1.141
CN - Cina 842
SE - Svezia 758
DE - Germania 686
SG - Singapore 602
VN - Vietnam 438
IN - India 231
IE - Irlanda 188
TG - Togo 165
FR - Francia 153
RU - Federazione Russa 153
UA - Ucraina 127
NG - Nigeria 97
ZA - Sudafrica 91
EE - Estonia 88
HR - Croazia 81
JP - Giappone 75
BG - Bulgaria 65
CH - Svizzera 58
FI - Finlandia 49
CI - Costa d'Avorio 48
BE - Belgio 46
JO - Giordania 41
AT - Austria 29
CA - Canada 24
ID - Indonesia 23
KR - Corea 22
NL - Olanda 18
EU - Europa 15
GR - Grecia 15
IR - Iran 14
PK - Pakistan 14
TR - Turchia 13
RO - Romania 12
SC - Seychelles 10
AU - Australia 9
PL - Polonia 9
HK - Hong Kong 7
UZ - Uzbekistan 6
IL - Israele 5
LT - Lituania 5
BR - Brasile 4
LB - Libano 4
LU - Lussemburgo 3
MY - Malesia 3
NZ - Nuova Zelanda 3
BD - Bangladesh 2
DK - Danimarca 2
ES - Italia 2
HU - Ungheria 2
MK - Macedonia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BO - Bolivia 1
CL - Cile 1
DZ - Algeria 1
EC - Ecuador 1
EG - Egitto 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LV - Lettonia 1
MD - Moldavia 1
NO - Norvegia 1
PE - Perù 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TW - Taiwan 1
Totale 14.064
Salva come PNG Salva come JPEG
Città #
Southend 1.038
Fairfield 741
Chandler 657
Singapore 537
Ashburn 502
Bologna 462
Santa Clara 428
Houston 422
Ann Arbor 353
Woodbridge 335
Wilmington 316
Seattle 292
Cambridge 256
Princeton 249
Dublin 188
Boardman 165
Lomé 165
Dong Ket 149
Nanjing 107
Padova 107
Westminster 106
Abeokuta 96
Milan 78
Berlin 75
Beijing 65
Sofia 65
Shenyang 59
Jinan 57
New York 57
Jacksonville 56
Saint Petersburg 54
Abidjan 48
Redwood City 48
San Diego 47
Bern 46
Florence 45
Medford 45
Brussels 44
Helsinki 44
Tokyo 44
Changsha 41
Amman 40
Turin 40
Frankfurt am Main 38
Bremen 37
Nanchang 34
Redmond 34
Hebei 33
Guangzhou 30
Vienna 27
Des Moines 24
Dearborn 22
Rome 22
Jakarta 21
Tianjin 21
Hangzhou 20
Zhengzhou 20
Jiaxing 19
Falls Church 18
Shanghai 18
Norwalk 17
Haikou 16
Tappahannock 15
Mountain View 14
Sejong 13
Toronto 13
Valsamoggia 13
Lanzhou 12
Phoenix 12
Taiyuan 12
Verona 12
Bühl 11
Forlì 11
Mülheim 11
Parma 11
Los Angeles 10
Mahé 10
Kunming 9
London 9
Taizhou 9
Amsterdam 8
Chicago 8
Falkenstein 8
Ferrara 8
Olalla 8
Ravenna 8
Reggio Emilia 8
Buffalo 7
Castiglione Olona 7
Fuzhou 7
Hefei 7
Locri 7
Marzabotto 7
Paris 7
San Francisco 7
Shenzhen 7
Cesena 6
Council Bluffs 6
Menfi 6
Moscow 6
Totale 9.590
Salva come PNG Salva come JPEG
Nome #
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 219
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 210
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 198
Clinical and molecular insights in erythropoiesis regulation of signal transduction pathways in myelodysplastic syndromes and β-thalassemia 183
Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. 182
Inositide-Dependent Nuclear Signalling in Health and Disease 172
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 167
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide 164
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes 163
Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. 162
Nuclear inositide signaling and cell cycle 161
PLC-β1 and cell differentiation: An insight into myogenesis and osteogenesis 158
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 157
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 154
Inositide signaling in the nucleus: From physiology to pathology. 154
B-all complexity: Is targeted therapy still a valuable approach for pediatric patients? 152
Inositide signaling: Nuclear targets and involvement in myelodysplastic syndromes 149
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 149
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes 149
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 147
null 144
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 144
Nuclear phospholipase C isoenzyme imbalance leads to pathologies in brain, hematologic, neuromuscular, and fertility disorders 142
Revisiting nuclear phospholipase C signalling in MDS 141
Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS 141
Specific presence of PKC isoforms in low and fast proliferation Moris hepatoma cells 138
Nuclear Inositide Signaling via Phospholipase C 138
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 137
Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells 137
Multiple forms of PKR present in the nuclei of acute leukemia cells represent an active kinase that is responsive to stress 136
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 134
Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes 132
Protein kinase C involvement in cell cycle modulation 130
Effect of PKC inhibition on low and fast proliferating Morris rat hepatoma cell line progression 129
Nuclear inositol lipid metabolism: more than just second messenger generation? 129
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 128
Nuclear phospholipase C beta1 and cellular differentiation. 127
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 127
Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome. 127
Effect of azacitidine on inositide-dependent signalling pathways in low-risk MDS patients 123
Azacitidine low-dose schedule in low-risk myelodysplastic syndromes. Clinical results of a multicenter phase II study 123
Frequent Elevation of Akt Kinase Phosphorylation in Blood Marrow and Peripheral Blood Mononuclear Cells from High Risk myelodysplastic Syndrome Patients 121
Nuclear inositide signaling in myelodysplastic syndromes. 120
Nuclear Localization of Diacylglycerol Kinase Alpha in K562 Cells Is Involved in Cell Cycle Progression 120
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 119
PLC and PI3K/Akt/mTOR signalling in disease and cancer 118
Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology 118
Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia 118
Modulation of nuclear PI-PLCbeta1 during cell differentiation 117
Inositide-dependent phospholipase C signaling mimics insulin in skeletal muscle differentiation by affecting specific regions of the cyclin D3 promoter 116
Physiology and pathology of nuclear phospholipase C beta1 115
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 115
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 115
Role of inositide signalling regulation in higher-risk MDS patients during epigenetic therapy 114
Nuclear Nox4-Derived Reactive Oxygen Species in Myelodysplastic Syndromes 114
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 114
Cancer therapy and treatments during COVID-19 era 113
The physiology and pathology of inositide signaling in the nucleus 112
PI-PLCβ1 gene copy number alterations in breast cancer 111
Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics 111
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment 111
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells 111
Phospholipase C-β1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation 111
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 110
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 109
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resisten human T-acute leukemia cells by a JNK-dependent mechanism 107
Recent advances in MDS mutation landscape: Splicing and signalling 107
PKR Activity Is Required for Acute Leukemic Cell Maintenance and Growth: A Role for PKR-Mediated Phosphatase Activity to Regulate GSK-3 Phosphorylation. 105
Molecular Mechanisms Underlying Psychological Stress and Cancer 104
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 104
Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS) 104
Unravelling Heterogeneity of Amplified Human Amniotic Fluid Stem Cells Sub-Populations 104
Nuclear PI-PLCbeta1-Lamin B1 complex signalling during cell cycle progression in human erytholeukemia cells 103
null 103
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. 103
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. 103
Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. 103
EFFECT OF LENALIDOMIDE ON INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS 100
null 100
Epigenetic regulation of nuclear PLCbeta1 and Cyclin D3 during Azacitidine treatment 98
Phosphoinositide-dependent signaling in cancer: A focus on phospholipase C isozymes 98
Role of PLCγ1 in the modulation of cell migration and cell invasion in glioblastoma 98
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes 96
Nuclear PI-PLCβ1: An appraisal on targets and pathology 95
Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. 95
null 95
Nuclear inositide signaling: An appraisal of phospholipase C beta1 behavior in myelodysplastic and leukemia cells 94
Primary phospholipase C and brain disorders 92
PKC inhibitors induced apoptosis in Morris hepatoma 90
Phosphoinositide 3 Kinase signaling in human stem cells from reprogramming to differentiation: A tale in cytoplasmic and nuclear compartments 90
Subcellular localization relevance and cancer-associated mechanisms of diacylglycerol kinases 90
Phosphoinositide-specific phospholipase C in health and disease 88
PROLONGED HEMATOLOGIC AND MOLECULAR RESPONSE AFTER A LIMITED NUMBER OF AZACITIDINE CYCLES IN LOW-RISK MYELODYSPLASTIC SYNDROMES 86
Epigenetic Regulation of Nuclear PI-PLCbeta1 Signalling Pathway in Low-Risk MDS Patients During Azacitidine Treatment 86
ROLE OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS ON EPO-INDUCED EYTHROID DIFFERENTIATION IN LOW-RISK MDS PATIENTS 84
SELECTIVE EFFECT OF LENALIDOMIDE ON CELL CYCLE AND INOSITIDE-DEPENDENT ERYTHROID SIGNALLING IN DEL(5Q) CELLS AND MYELODYSPLASTIC SYNDROMES (MDS) 84
Glycogen Synthase Kinase-3 and phospholipase C-beta signalling: Roles and possible interactions in myelodysplastic syndromes and acute myeloid leukemia 83
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes 82
GENE EXPRESSION OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS IN MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 82
Reply to Herens et al. 82
Totale 12.248
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.674
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.674
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.753 0 0 0 0 0 0 383 365 474 198 163 170
2020/20211.828 354 105 82 63 40 95 51 122 185 78 90 563
2021/20222.543 261 37 167 203 226 130 79 147 91 353 418 431
2022/20233.015 284 390 163 403 275 245 163 197 466 61 201 167
2023/20241.103 69 165 98 88 135 164 36 47 68 107 55 71
2024/20251.886 143 434 301 192 616 167 33 0 0 0 0 0
Totale 14.509